Kane Biotech Company Description
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.
The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections.
Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name.
In addition, the company offers shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate Acne Vulgaris.
Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Contact Details
Address: 290-100 Innovation Drive Winnipeg, R3T 6G2 Canada | |
| Phone | 204-453-1301 |
| Website | kanebiotech.com |
Stock Details
| Ticker Symbol | KNBIF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA4838092084 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC | Interim Chief Executive Officer, Director and Member of Scientific Advisory Board |
| Ray Dupuis | Chief Financial Officer |
| Lori Christofalos | Chief Quality Officer |
| Dr. Gregory S. Schultz Ph.D. | Chief Scientific Officer and Member of Scientific Advisory Board |
| Lorne Gorber | Investor Relations |
| Nicole Sendey | Investor Relations Adviser |